de Verneuil Vanina's Form 4 filing
Vir Biotechnology, Inc. (VIR) · filed Feb 25, 2025
- Accession no.
- 0001628280-25-007690
- Filed
- Feb 25, 2025
- Trade date
- Feb 22-24, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $48.6K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| de Verneuil VaninaCIK 0002036234 | Officer (EVP and General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 22, 2025 | Common Stock | AGrant or awardAcquired | +35,000 | $0.00 | $0 | 91,973 | Direct | |
| Feb 24, 2025 | Common Stock | SSaleDisposed | −5,140 | $9.45 | −$48,573 | 86,833 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 22, 2025 | Common Stock | AGrant or awardAcquired | +70,000 | $0.00 | $0 | 70,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.